WO2015026454A1 - Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c - Google Patents

Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c Download PDF

Info

Publication number
WO2015026454A1
WO2015026454A1 PCT/US2014/046685 US2014046685W WO2015026454A1 WO 2015026454 A1 WO2015026454 A1 WO 2015026454A1 US 2014046685 W US2014046685 W US 2014046685W WO 2015026454 A1 WO2015026454 A1 WO 2015026454A1
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
interferon
ns5a
compounds
antiviral
Prior art date
Application number
PCT/US2014/046685
Other languages
English (en)
Inventor
Alan Xiangdong Wang
Omar D. Lopez
Yong Tu
Makonen Belema
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Priority to EP14748036.2A priority Critical patent/EP3021846A1/fr
Priority to US14/904,817 priority patent/US9717712B2/en
Priority to CN201480050770.5A priority patent/CN105555266B/zh
Priority to JP2016527033A priority patent/JP2016525114A/ja
Publication of WO2015026454A1 publication Critical patent/WO2015026454A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La présente invention concerne de manière générale des composés antiviraux, et plus spécifiquement des associations de composés qui peuvent inhiber la fonction de la protéine NS5A codée par le virus de l'hépatite C (VHC), des compositions comprenant de telles associations, et des procédés d'inhibition de la fonction de la protéine NS5A.
PCT/US2014/046685 2013-07-02 2014-07-15 Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c WO2015026454A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP14748036.2A EP3021846A1 (fr) 2013-07-17 2014-07-15 Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c
US14/904,817 US9717712B2 (en) 2013-07-02 2014-07-15 Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN201480050770.5A CN105555266B (zh) 2013-07-17 2014-07-15 用于治疗丙型肝炎病毒的包含三环十六碳六烯衍生物的组合产品
JP2016527033A JP2016525114A (ja) 2013-07-17 2014-07-15 Ｃ型肝炎ウイルスの治療に使用するためのトリシクロヘキサデカヘキサエン誘導体を含む組み合わせ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361847388P 2013-07-17 2013-07-17
US61/847,388 2013-07-17

Publications (1)

Publication Number Publication Date
WO2015026454A1 true WO2015026454A1 (fr) 2015-02-26

Family

ID=51293156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/046685 WO2015026454A1 (fr) 2013-07-02 2014-07-15 Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c

Country Status (4)

Country Link
EP (1) EP3021846A1 (fr)
JP (1) JP2016525114A (fr)
CN (1) CN105555266B (fr)
WO (1) WO2015026454A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017076194A1 (fr) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 Composés à activité inhibitrice contre le virus de l'hépatite c, leur procédé de préparation et leur utilisation
WO2017076187A1 (fr) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 Dérivé 1,4(1,4)-diphénylhexacyclophane-12,43-diyle, procédé de préparation et application de celui-ci
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093867A1 (fr) 2005-02-28 2006-09-08 The Rockefeller University Structure de la protéine ns5a du virus de l’hépatite c
WO2012009394A2 (fr) 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Procédés pour l'identification de combinaisons de composés ciblant de ns5a qui agissent synergiquement pour inhiber la réplication du virus de l'hépatite c
WO2012166716A2 (fr) * 2011-05-27 2012-12-06 Achillion Pharmaceuticals, Inc. Aliphanes, cyclophanes, hétéraphanes, hétérophanes, hétéro-hétéraphanes et métallocènes substitués utiles pour le traitement des infections par le virus de l'hépatite c
WO2013106520A1 (fr) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8344155B2 (en) * 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093867A1 (fr) 2005-02-28 2006-09-08 The Rockefeller University Structure de la protéine ns5a du virus de l’hépatite c
WO2012009394A2 (fr) 2010-07-16 2012-01-19 Bristol-Myers Squibb Company Procédés pour l'identification de combinaisons de composés ciblant de ns5a qui agissent synergiquement pour inhiber la réplication du virus de l'hépatite c
WO2012166716A2 (fr) * 2011-05-27 2012-12-06 Achillion Pharmaceuticals, Inc. Aliphanes, cyclophanes, hétéraphanes, hétérophanes, hétéro-hétéraphanes et métallocènes substitués utiles pour le traitement des infections par le virus de l'hépatite c
WO2013106520A1 (fr) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 313, 2004, pages 42
HEPATOLOGY, vol. 38, 2003, pages 1282
J. GASTROENTEROL., vol. 38, 2003, pages 567
K.-J. PARK ET AL., J. BIOL. CHEM., 2003, pages 30711 - 30718
L. HUANG, J. BIOL. CHEM., vol. 280, 2005, pages 36417
M. GAO ET AL., NATURE, 2010
N. APPEL ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 9833
PHARMACEUTICAL RESEARCH, vol. 3, no. 6, 1986, pages 318
R. A. LOVE ET AL., J. VIROL, vol. 83, 2009, pages 4395
S. L. TAN ET AL., VIROLOGY, vol. 284, 2001, pages 1 - 12
T. L. TELLINGHUISEN ET AL., NATURE, vol. 435, 2005, pages 374

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2017076194A1 (fr) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 Composés à activité inhibitrice contre le virus de l'hépatite c, leur procédé de préparation et leur utilisation
WO2017076187A1 (fr) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 Dérivé 1,4(1,4)-diphénylhexacyclophane-12,43-diyle, procédé de préparation et application de celui-ci
CN108348504A (zh) * 2015-11-06 2018-07-31 江苏豪森药业集团有限公司 具有抑制hcv活性的化合物及其制备方法和应用
CN108349907A (zh) * 2015-11-06 2018-07-31 江苏豪森药业集团有限公司 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
CN108348504B (zh) * 2015-11-06 2021-06-29 江苏豪森药业集团有限公司 具有抑制hcv活性的化合物及其制备方法和应用
CN108349907B (zh) * 2015-11-06 2021-08-31 江苏豪森药业集团有限公司 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用

Also Published As

Publication number Publication date
CN105555266B (zh) 2018-11-30
CN105555266A (zh) 2016-05-04
JP2016525114A (ja) 2016-08-22
EP3021846A1 (fr) 2016-05-25

Similar Documents

Publication Publication Date Title
EP2784075B1 (fr) Inhibiteurs du virus de l'hépatite C
EP2300491B1 (fr) Inhibiteurs du virus de l hépatite c
US9340520B2 (en) Hepatitis C virus inhibitors
EP2250163B1 (fr) Inhibiteurs du virus de l'hépatite c
ES2674401T3 (es) Inhibidores del virus de la hepatitis C
EP2707365B1 (fr) Inhibiteurs du virus de l'hépatite c
WO2013055563A1 (fr) Composés pour le traitement de l'hépatite c
WO2015026454A1 (fr) Associations comprenant des dérivés de tricyclohexadécahexène destinées à être utilisées pour le traitement du virus de l'hépatite c
US20160311806A1 (en) 4,4'-biphenyldiyl-bis-(1 h-imidazolyl) derivatives as hepatitis hcv inhibitors
US9775831B2 (en) Combinations comprising biphenyl derivatives for use in the treatment of HCV
US9717712B2 (en) Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US10617675B2 (en) Hepatitis C virus inhibitors
EP2964630B9 (fr) Composés de pyrimidine pour le traitement de l'hépatite c
US8987265B2 (en) Substituted 1,3,5-triazine derivatives of fused bicyclic oxalamide compounds for treatment of Hepatitis C
EP2948151B1 (fr) Dérivés d'ammonium pour le traitement de l'hépatite c
NZ615067B2 (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480050770.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14748036

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2014748036

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14904817

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016527033

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE